No images? Click here Friday, 25 September 2020 MEDIA ADVISORY US$35 billion price tag to end the acute phase of the pandemic Partners lay out investment needed to speed up access to COVID-19 diagnostics, vaccines and treatments The ACT-Accelerator is the only global initiative offering a solution to speed up the end of the COVID-19 pandemic. Launched on 24 April 2020, it combines public and private sector expertise and institutions from around the world to accelerate the development, regulatory approval, scale-up, delivery and equitable allocation of COVID-19 tests, treatments and vaccines. The ACT-Accelerator needs US$35 billion to meet the goal of developing new tools and producing and delivering 2 billion vaccine doses, 245 million treatments and 500 million diagnostic tests over the next year. With the largest portfolio of COVID-19 tools in the world, investing in the ACT-Accelerator increases the probability of being able to access the “winning candidate” and hedges the risk that countries that have already entered individual bilateral agreements end up with products that are not viable. The economic rationale for investment is clear:
In just 5 months, the ACT-Accelerator has made significant progress, as evidenced by the status report, published today:
Leaders will next meet on 30th September at a high-level side event during the United Nations General Assembly to discuss the work of the ACT-Accelerator, and the financial commitments needed. Media contact: You are receiving this email because you are included on a WHO mail list. |
Your Highlights
Comments
Post a Comment